the clinicopathological features and therapy in 19 patients with
kidney disease accompanied by hepatitis C viral infection,
including 12 patients with mesangial proliferative
glomerulonephritis (including eight with IgA nephropathy), six with
membranoproliferative glomerulonephritis (MPGN), and one with
membranous nephropathy. Persistent hematuria and/or proteinuria (10
patients) was the most common finding, followed by nephrotic
syndrome (8 patients). Cryoglobulinemia was detected in six of 19
patients examined (four of six patients with MPGN), Analysis of
hepatitis C virus (HCV)-RNA genotype in 13 patients revealed that
nine of them had type II genotype. All four patients with MPGN, who
had serum positive for HCV-RNA, had type II genotype. Five patients
were treated with interferon-alpha (IFN-alpha) without a
demonstrable effect on renal impairment, whereas five of 11
patients treated with steroids showed improvement of the renal
impairment. During the course of steroid therapy, the serum titer
of HCV-RNA decreased in 5 of 7 patients. These observations suggest
that HCV infection may be associated with several forms of
glomerulonephritis. Type II HCV-RNA may have a strong association
with MPGN in Japan. Steroid therapy is not contraindicated in
patients with HCV-associated nephropathy if they are resistant to
INTERNAL MEDICINE 1996 JUL;35(7):529-533
Authors: KOMATSUDA A, IMAI H, WAKUI H, HAMAI K, OHTANI H, KODAMA T,
OYAMA Y, MIURA AB, NAKAMOTO Y
Decrease in the Number of People Living with HCV
John Ward, the CDC’s director of the division of viral hepatitis, said in a telephone interview, "While the total number of U.S. patients may be declining as people die from the disease, the rate of new cases is increasing as younger people -- mostly intravenous drug uses -- become infected."
Is There a Role for Vitamin D in Hepatitis C Treatment?
Researchers in Scotland will determine if Vitamin D can have a positive impact on Hepatitis C cure rates when used in combination with currently available treatment therapies. If confirmed, a less expensive method of treatment could emerge.
Hep C News: Milk Thistle Research Confirms Liver Benefit
California research favors silibin for saving the liver from a hazardous mushroom toxin. Besides treating death cap mushroom consumption, silibin’s liver-protective strengths also make it valuable for other liver-damaging problems – especially the Hepatitis C virus.